Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis
Open accessThe DOI matches its Crossref record.
Abstract
Everolimus has been used widely in cancer patients and is associated with the development of hyperglycemia. Due to confounding factors, its specific impact on hyperglycemia has not been well understood. We performed a meta-analysis of randomized controlled trials to determine the risk of hyperglycemia attributable to everolimus in cancer patients of varying tumor types. MATERIAL AND METHODS: PubMed and American Society of Clinical Oncology conference abstracts up to June 2015 were systematically searched. Eligible studies included randomized controlled trials (RCTs) in which everolimus was compared to placebo in cancer patients with or without other agents. Heterogeneity tests were performed to examine between-study differences in hyperglycemia, and the incidence and relative risk of all- and high-grade hyperglycemia attributable to everolimus were determined using both random- or fixed-effects models. RESULTS: A total of seven phase III and two phase II RCTs with various tumors, encompassing a total of 3879 cancer patients, were included in our analysis. Everolimus significantly increased the risk of all-grade (RR =2.60, 95% CI 2.03-3.31, p < 0.001) and high-grade (RR =3.0, 95% CI 1.72-5.23; p < 0.001) hyperglycemia. The incidences of all- and high-grade hyperglycemia attributable to everolimus were 6.8% (95% CI 3.4-13.2%) and 2.5% (95% CI 1.2-4.9%), respectively. The everolimus-specific risk of all-grade hyperglycemia varied significantly with tumor types (p < 0.001), with the highest incidence seen in renal cell carcinoma (RCC) (27.2%, 95% CI 22.2-32.8%) and the lowest in breast cancer (3.3%, 95% CI 1.3-8.2%). No significant variation was found between everolimus alone or everolimus in combination with other agents. Similar results were also found for the risk of high-grade hyperglycemia attributable to everolimus. CONCLUSION: The specific risk of hyperglycemia attributable to everolimus may vary significantly with tumor types. Close monitoring should be given to patients at high risk, such as RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
Blagosklonny, M. V. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1822-8 · Cited by 74
A guideline for the outpatient management of glycaemic control in people with cancer
Joharatnam‐Hogan, N., Chambers, P., Dhatariya, K., Board, R., & the Joint British Diabetes Society for Inpatient Care (JBDS), U. C. B. (. (2022) · Diabetic Medicine · doi:10.1111/dme.14636 · Cited by 50
Immune checkpoints inhibitors and hyperglycemia: A meta-analysis of randomized controlled trials
Monami, M., Naletto, L., Nreu, B., Dicembrini, I., Sesti, G., & Mannucci, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108115 · Cited by 12
Metadata
- Authors
- Xu, K. Y., Shameem, R., & Wu, S.
- Venue
- Acta Oncologica
- Published
- 2016-05-04
- Volume
- 55
- Issue
- 9-10
- Pages
- 1196-1203
- ISSN
- 0284-186X (ISSN-L)
- 1651-226X
- OpenAlex
- W2346298590
- Cited by
- 26
- References
- 0
- FWCI
- 0.17
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. https://app.cochat.ai/papers/10.3109/0284186x.2016.1168939
- The paper
- Xu, K. Y., Shameem, R., & Wu, S. (2016). Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. Acta Oncologica. https://doi.org/10.3109/0284186x.2016.1168939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.